Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/BIND-014> ?p ?o }
Showing triples 1 to 21 of
21
with 100 triples per page.
- BIND-014 abstract "BIND-014 is a targeted polymeric nanoparticle, and is an investigational therapeutic drug in phase 2 clinical trials for various cancers, eg. metastatic prostate cancerBIND-014 is an Accurin nanomedicine produced by Bind Therapeutics Inc. BIND-014 targets prostate-specific membrane antigen (PSMA), which is expressed on prostate cancer cells and the blood vessels of many types of solid tumors, and contains docetaxel as the cytotoxic agent.Positive results in non-small cell lung cancer were presented in late 2014.".
- BIND-014 wikiPageID "48525722".
- BIND-014 wikiPageLength "1486".
- BIND-014 wikiPageOutDegree "7".
- BIND-014 wikiPageRevisionID "704200334".
- BIND-014 wikiPageWikiLink Accurin.
- BIND-014 wikiPageWikiLink Bind_Therapeutics.
- BIND-014 wikiPageWikiLink Category:Nanomedicine.
- BIND-014 wikiPageWikiLink Docetaxel.
- BIND-014 wikiPageWikiLink Glutamate_carboxypeptidase_II.
- BIND-014 wikiPageWikiLink Non-small-cell_lung_carcinoma.
- BIND-014 wikiPageWikiLink Prostate_cancer.
- BIND-014 wikiPageWikiLinkText "BIND-014".
- BIND-014 wikiPageUsesTemplate Template:Reflist.
- BIND-014 wikiPageUsesTemplate Template:Treatment-stub.
- BIND-014 subject Category:Nanomedicine.
- BIND-014 hypernym Nanoparticle.
- BIND-014 comment "BIND-014 is a targeted polymeric nanoparticle, and is an investigational therapeutic drug in phase 2 clinical trials for various cancers, eg. metastatic prostate cancerBIND-014 is an Accurin nanomedicine produced by Bind Therapeutics Inc.".
- BIND-014 label "BIND-014".
- BIND-014 wasDerivedFrom BIND-014?oldid=704200334.
- BIND-014 isPrimaryTopicOf BIND-014.